Who We Are:
Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has exhibited promising initial data across all three trials: APEX in AdvSM, SUMMIT in NonAdvSM and PEAK in GIST, including an encouraging safety profile across 600+ patients in single agent and combination dosing.
The Role: Cogent Biosciences is seeking an Associated Director of Patient Marketing to design and deliver a best-in-class, end-to-end patient experience for the launch of Bezuclastinib in Systemic Mastocytosis & Gastrointestinal Stromal (GIST) Tumors. Reporting to the Sr. Director of Patient Marketing, this individual will help shape how patients are identified, educated, activated, and supported throughout their disease and treatment journey. Serving as the internal champion for the patient voice, the role translates complex clinical data into meaningful, patient-centric resources and drives high-impact media strategies to reach those in need. In close collaboration with HCP marketing and patient services, this leader will help ensure a seamless transition from awareness to access and ongoing support. The ideal candidate brings deep rare disease and/or oncology expertise and a strong foundation in patient-centric marketing.
Responsibilities:
Responsibilities Patient Strategy
Resource and Digital Ecosystem Development Lead the creation of patient-facing materials and partner closely with the HCP Marketing and Sales teams to ensure patient resources are effectively utilized by the field in the clinical setting
Leadership and Collaboration
Qualifications:
Knowledge And Skills
Salary Range:
$195,000- $230,000 USD
Waltham, MA: Our headquarters is located in the Greater Boston life sciencescommunity, with an open, collaborative office environment designedto support teamwork and connection. Employees benefit from convenient on-site amenities, including free on-site parking and gym facilities in the building.
Boulder, CO: Our Boulder location is home to Cogent’s discovery research organization and a key scientific hub with strong leadership based on site Situated in the greater Denver-Boulder biopharmaceutical corridor, this office plays a central role in advancing our discovery efforts and pipeline
Our Offer To You
At Cogent Biosciences, we offer a competitive salary, bonus, and ongoing stock awards, alongside a benefits package that sets us apartWe cover 100% of medical, dental, and vision premiums for you and your family, and help reduce out-of-pocket costs by funding up to 75% of in-network deductiblesOur benefits also include a 401(k) match with immediate vesting, generous paid time off, 12 weeks of fully paid parental leave, paid family and medical leave for all employees regardless of location, and company-paid short-term disability coverage for up to 20 weeksAdditionalperks likewellness programs, tuition reimbursement, and inclusive family-forming support help you thrive at work and beyond.
We are proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability, or any other status protected under federal, state, or local law. All employment is decided on the basis of qualifications, merit, and business need
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.
